Informazioni cliniche
La colangite sclerosante primaria (CSP) è una malattia cronica del fegato con distruzione progressiva dei dotti biliari. La CSP ha una prevalenza di circa 8-14 pazienti su 100.000 persone. Gli uomini sono più frequentemente colpiti dalla malattia rispetto alle donne (60-80%) e la malattia viene diagnosticata principalmente all'età di 30-60 anni. La CSP si manifesta più spesso in pazienti con malattie infiammatorie croniche dell'intestino (85-90% colite ulcerosa e 10-15% malattia di Crohn). La maggior parte dei pazienti con CSP presenta autoanticorpi contro i granulociti (pANCA) il cui principale antigene bersaglio è la lattoferrina legata al DNA.
Diagnostica
La colangiografia è il metodo più rilevante per ottenere una diagnosi affidabile. Sebbene nella CSP siano presenti numerosi autoanticorpi, non si tratta di una tipica malattia autoimmune. Tuttavia, può essere associata a fenomeni autoimmuni nell'infanzia e alla presenza di alti titoli di autoanticorpi (ANA, ANCA e ASMA). Nei casi sospetti di sindrome da sovrapposizione con epatite autoimmune o colangite biliare primaria (fino al 10% dei casi), i test anticorpali sierologici possono fornire ulteriori informazioni diagnostiche.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| EUROLINE |
EUROLINE Anti-MPO, -PR3 and -GBM (IgG) myeloperoxidase proteinase 3 (PR3) glomerular basement membrane |
EUROLINE | IgG IgG |
16 x 01 64 x 01 |
DL 1200-1601-3 G DL 1200-6401-3 G |
||
| ChLIA | IDS ANCA/GBM Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-AI17301 | ||
| ChLIA |
IDS AMA (M2) MIT3 |
antigenic coated magnetic particles | MIT3 |
quantitative |
50 x 01 |
IS-AI18011 | |
| ChLIA | IDS Liver Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-AI18301 | ||
| IIFT |
antibodies against granulocyte cytoplasm, cytoplasmic pattern (cANCA control, PR3 ab control) |
IgG |
05 x 02 |
CA 1200-0502 | |||
| IIFT |
antibodies against granulocyte cytoplasm, perinuclear pattern (pANCA control) |
IgG |
05 x 02 |
CA 1210-0502 | |||
| IIFT |
antibodies against granulocyte cytoplasm, perinuclear pattern (pANCA control, MPO ab control) |
IgG |
05 x 02 |
CA 1211-0502 | |||
| IIFT |
cytoplasm of granulocytes (cANCA, pANCA), nuclei of granulocytes (GS-ANA) |
granulocytes, ethanol-fixed |
human | IgG IgG IgG IgG |
10 x 05 10 x 10 180 x 10 20 x 05 10 x 05 10 x 10 20 x 05 |
FA 1200-1005 FA 1200-1010 FA 1200-18010 FA 1200-2005 FB 1200-1005 FB 1200-1010 FB 1200-2005 |
|
| IIFT |
granulocytes (cANCA, pANCA) |
granulocytes, formaldehyde-fixed |
human | IgG IgG |
10 x 05 10 x 10 10 x 05 10 x 10 |
FA 1201-1005 FA 1201-1010 FB 1201-1005 FB 1201-1010 |
|
| IIFT |
Granulocyte Mosaic 13 cANCA, pANCA, GS-ANA cell nuclei (ANA), cANCA, pANCA cANCA, pANCA |
3 BIOCHIPs per field: granulocytes (EOH) HEp-2+granulocytes (EOH) granulocytes (HCHO) |
human human human |
IgG IgG IgG IgG IgG IgG |
10 x 05 10 x 10 10 x 50 120 x 10 20 x 05 20 x 10 10 x 05 10 x 10 10 x 50 20 x 05 20 x 10 |
FA 1201-1005-13 FA 1201-1010-13 FA 1201-1050-13 FA 1201-12010-13 FA 1201-2005-13 FA 1201-2010-13 FB 1201-1005-13 FB 1201-1010-13 FB 1201-1050-13 FB 1201-2005-13 FB 1201-2010-13 |
|
| IIFT |
Granulocyte Mosaic 15 cANCA, pANCA, GS-ANA cell nuclei (ANA), cANCA, pANCA |
2 BIOCHIPs per field: granulocytes (EOH) HEp-2+granulocytes (EOH) |
human human |
IgG IgG IgG IgG |
10 x 05 10 x 10 20 x 05 20 x 10 10 x 05 10 x 10 20 x 05 20 x 10 |
FA 1201-1005-15 FA 1201-1010-15 FA 1201-2005-15 FA 1201-2010-15 FB 1201-1005-15 FB 1201-1010-15 FB 1201-2005-15 FB 1201-2010-15 |
|
| IIFT |
Granulocyte Mosaic 2 cANCA, pANCA, GS-ANA cANCA, pANCA |
2 BIOCHIPs per field: granulocytes (EOH) granulocytes (HCHO) |
human human |
IgG IgG IgG IgG |
10 x 05 10 x 10 20 x 05 20 x 10 10 x 05 10 x 10 20 x 05 20 x 10 |
FA 1201-1005-2 FA 1201-1010-2 FA 1201-2005-2 FA 1201-2010-2 FB 1201-1005-2 FB 1201-1010-2 FB 1201-2005-2 FB 1201-2010-2 |
|
| IIFT |
EUROPLUS Granulocyte Mosaic 22 cANCA, pANCA, GS-ANA cANCA, pANCA pANCA: myeloperoxidase (MPO) cANCA: proteinase 3 (PR3) |
4 BIOCHIPs per field: granulocytes (EOH) granulocytes (HCHO) MPO BIOCHIPs PR3 BIOCHIPs |
human human |
IgG IgG IgG |
10 x 05 10 x 10 20 x 05 10 x 05 10 x 10 |
FA 1201-1005-22 FA 1201-1010-22 FA 1201-2005-22 FB 1201-1005-22 FB 1201-1010-22 |
|
| IIFT |
EUROPLUS Granulocyte Mosaic 25 cANCA, pANCA, GS-ANA cell nuclei (ANA), cANCA, pANCA cANCA, pANCA glomerular basement membrane (GBM) pANCA: myeloperoxidase (MPO) cANCA: proteinase 3 (PR3) |
6 BIOCHIPs per field: granulocytes (EOH) HEp-2+granulocytes (EOH) granulocytes (HCHO) GBM BIOCHIPs MPO BIOCHIPs PR3 BIOCHIPs |
human human human |
IgG IgG IgG IgG |
10 x 05 10 x 10 20 x 05 20 x 10 10 x 05 20 x 05 20 x 10 |
FA 1201-1005-25 FA 1201-1010-25 FA 1201-2005-25 FA 1201-2010-25 FB 1201-1005-25 FB 1201-2005-25 FB 1201-2010-25 |
|
| IIFT |
EUROPLUS Granulocyte Mosaic 32 cANCA, pANCA, GS-ANA cANCA, pANCA cell nuclei (ANA), cANCA, pANCA pANCA: myeloperoxidase (MPO) cANCA: proteinase 3 (PR3) |
5 BIOCHIPs per field: granulocytes (EOH) granulocytes (HCHO) HEp-2+granulocytes (EOH) MPO BIOCHIPs PR3 BIOCHIPs |
human human human |
IgG IgG IgG IgG |
10 x 05 10 x 10 20 x 05 20 x 10 10 x 05 10 x 10 20 x 05 20 x 10 |
FA 1201-1005-32 FA 1201-1010-32 FA 1201-2005-32 FA 1201-2010-32 FB 1201-1005-32 FB 1201-1010-32 FB 1201-2005-32 FB 1201-2010-32 |
|
| IIFT |
cytoplasm of granulocytes (cANCA, pANCA), nuclei of granulocytes (GS-ANA) EUROPattern |
granulocytes, ethanol-fixed |
human | IgG EB IgG EB IgG EB IgG EB IgG EB |
10 x 05 10 x 10 120 x 10 20 x 05 20 x 10 |
FC 1200-1005 FC 1200-1010 FC 1200-12010 FC 1200-2005 FC 1200-2010 |
|
| IIFT |
granulocytes (cANCA, pANCA) EUROPattern |
granulocytes, formaldehyde-fixed |
human | IgG EB IgG EB IgG EB |
10 x 05 10 x 10 20 x 05 |
FC 1201-1005 FC 1201-1010 FC 1201-2005 |
|
| IIFT |
Granulocyte Mosaic 13 EUROPattern cANCA, pANCA, GS-ANA, EUROPattern cell nuclei (ANA), cANCA, pANCA cANCA, pANCA, EUROPattern |
3 BIOCHIPs per field: granulocytes (EOH) HEp-2+granulocytes (EOH) granulocytes (HCHO) |
human human human |
IgG EB IgG EB IgG EB IgG EB IgG EB IgG EB IgG EB IgG EB |
10 x 05 10 x 10 120 x 10 20 x 05 20 x 10 24 x 50 10 x 05 20 x 10 |
FC 1201-1005-13 FC 1201-1010-13 FC 1201-12010-13 FC 1201-2005-13 FC 1201-2010-13 FC 1201-2450-13 FW 1201-1005-13 FW 1201-2010-13 |
|
| IIFT |
Granulocyte Mosaic 15 EUROPattern cANCA, pANCA, GS-ANA, EUROPattern cell nuclei (ANA), cANCA, pANCA |
2 BIOCHIPs per field: granulocytes (EOH) HEp-2+granulocytes (EOH) |
human human |
IgG EB IgG EB IgG EB IgG EB IgG EB |
10 x 05 10 x 10 10 x 50 20 x 10 10 x 05 |
FC 1201-1005-15 FC 1201-1010-15 FC 1201-1050-15 FC 1201-2010-15 FW 1201-1005-15 |
|
| IIFT |
Granulocyte Mosaic 2 EUROPattern cANCA, pANCA, GS-ANA, EUROPattern cANCA, pANCA, EUROPattern |
2 BIOCHIPs per field: granulocytes (EOH) granulocytes (HCHO) |
human human |
IgG EB IgG EB IgG EB IgG EB IgG EB |
10 x 05 10 x 10 120 x 10 20 x 05 20 x 10 |
FC 1201-1005-2 FC 1201-1010-2 FC 1201-12010-2 FC 1201-2005-2 FC 1201-2010-2 |
|
| IIFT |
EUROPLUS Granulocyte Mosaic 22 EUROPattern cANCA, pANCA, GS-ANA, EUROPattern cANCA, pANCA, EUROPattern pANCA: myeloperoxidase (MPO), EUROPattern cANCA: proteinase 3 (PR3), EUROPattern |
4 BIOCHIPs per field: granulocytes (EOH) granulocytes (HCHO) MPO BIOCHIPs PR3 BIOCHIPs |
human human |
IgG EB IgG EB IgG EB |
10 x 05 10 x 10 20 x 10 |
FC 1201-1005-22 FC 1201-1010-22 FC 1201-2010-22 |
|
| IIFT |
EUROPLUS Granulocyte Mosaic 25 EUROPattern cANCA, pANCA, GS-ANA, EUROPattern cell nuclei (ANA), cANCA, pANCA cANCA, pANCA, EUROPattern glom. basement membrane (GBM), EUROPattern pANCA: myeloperoxidase (MPO), EUROPattern cANCA: proteinase 3 (PR3), EUROPattern |
6 BIOCHIPs per field: granulocytes (EOH) HEp-2+granulocytes (EOH) granulocytes (HCHO) GBM BIOCHIPs MPO BIOCHIPs PR3 BIOCHIPs |
human human human |
IgG EB IgG EB IgG EB IgG EB IgG EB IgG EB |
10 x 05 10 x 10 20 x 05 20 x 10 10 x 05 20 x 10 |
FC 1201-1005-25 FC 1201-1010-25 FC 1201-2005-25 FC 1201-2010-25 FW 1201-1005-25 FW 1201-2010-25 |
|
| IIFT |
EUROPLUS Granulocyte Mosaic 32 EUROPattern cANCA, pANCA, GS-ANA, EUROPattern cANCA, pANCA, EUROPattern cell nuclei (ANA), cANCA, pANCA pANCA: myeloperoxidase (MPO), EUROPattern cANCA: proteinase 3 (PR3), EUROPattern |
5 BIOCHIPs per field: granulocytes (EOH) granulocytes (HCHO) HEp-2+granulocytes (EOH) MPO BIOCHIPs PR3 BIOCHIPs |
human human human |
IgG EB IgG EB IgG EB IgG EB IgG EB IgG EB IgG EB |
10 x 05 10 x 10 120 x 10 20 x 05 20 x 10 10 x 05 10 x 10 |
FC 1201-1005-32 FC 1201-1010-32 FC 1201-12010-32 FC 1201-2005-32 FC 1201-2010-32 FW 1201-1005-32 FW 1201-1010-32 |
|
| ELISA |
ANCA-Profile ELISA (IgG) (proteinase 3, MPO, elastase, cathepsin G, BPI, lactoferrin separately) |
antigen-coated microplate wells |
native, human neutrophil granulocytes recombinant, human c-DNA expressed in human cell line |
semi-quantitative | IgG |
12 x 08 |
EA 1200-1208-1 G |
| ELISA |
Anti-PR3-hn-hr ELISA (IgG) cANCA: proteinase 3 |
antigen-coated microplate wells |
hn: native, human neutrophil granulocytes hr: recombinant, human c-DNA expressed in human cell line |
2/20/200 RU/ml | IgG |
96 x 01 |
EA 1201-9601-2 G |
| ELISA |
Anti-MPO ELISA (IgG) pANCA: myeloperoxidase |
antigen-coated microplate wells |
native, human neutrophil granulocytes |
2/20/200 RU/ml | IgG |
96 x 01 |
EA 1211-9601 G |
| EUROLINE |
positive control serum: IgG, human, 100x concentrated for DL 1200-X G |
IgG |
05 x 07 |
CL 1200-0507-2 G | |||
| EUROLINE |
EUROLINE Anti-MPO, -PR3 (IgG) myeloperoxidase proteinase 3 |
EUROLINE | IgG IgG |
16 x 01 64 x 01 |
DL 1200-1601-2 G DL 1200-6401-2 G |
||
| ChLIA | IDS MPO | antigenic coated magnetic particles | MPO |
quantitative |
50 x 01 |
IS-AI17011 | |
| ChLIA | IDS PR3-II | antigenic coated magnetic particles | PR3 |
quantitative |
50 x 01 |
IS-AI1702II1 | |
| ChLIA | Anti-PR3 ChLIA (IgG) | Antigen-coated magnetic particles | quantitative | IgG |
100 x 1 |
LA 1201-10010 G | |
| ChLIA | Anti-Myeloperoxidase ChLIA (IgG) | Antigen-coated magnetic particles | quantitative | IgG |
100 x 1 |
LA 1211-10010 G | |
| ChLIA | Control set Anti-PR3 ChLIA (IgG) | 2 x 0.4 ml control 1/2 | IgG |
02 x 02 |
LR 1201-20210 G | ||
| ChLIA | Control set Anti-Myeloperoxidase ChLIA (IgG) | 2 x 0.4 ml control 1/2 | IgG |
02 x 02 |
LR 1211-20210 G | ||
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||